Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Dynamic ploidy changes drive fluconazole resistance in human cryptococcal meningitis.

Stone NR, Rhodes J, Fisher MC, Mfinanga S, Kivuyo S, Rugemalila J, Segal ES, Needleman L, Molloy SF, Kwon-Chung J, Harrison TS, Hope W, Berman J, Bicanic T.

J Clin Invest. 2019 Mar 1;129(3):999-1014. doi: 10.1172/JCI124516. Epub 2019 Jan 28.

2.

Gene Essentiality Analyzed by In Vivo Transposon Mutagenesis and Machine Learning in a Stable Haploid Isolate of Candida albicans.

Segal ES, Gritsenko V, Levitan A, Yadav B, Dror N, Steenwyk JL, Silberberg Y, Mielich K, Rokas A, Gow NAR, Kunze R, Sharan R, Berman J.

MBio. 2018 Oct 30;9(5). pii: e02048-18. doi: 10.1128/mBio.02048-18.

3.

Antifungal tolerance is a subpopulation effect distinct from resistance and is associated with persistent candidemia.

Rosenberg A, Ene IV, Bibi M, Zakin S, Segal ES, Ziv N, Dahan AM, Colombo AL, Bennett RJ, Berman J.

Nat Commun. 2018 Jun 25;9(1):2470. doi: 10.1038/s41467-018-04926-x.

4.

Ethnic and ethical challenges in treatment planning: dealing with diversity in the 21st century.

Haskell BS, Segal ES.

Angle Orthod. 2014 Mar;84(2):380-2. doi: 10.2319/0003-3219-84.2.380. No abstract available.

PMID:
24601629
5.

Competitive and cooperative metabolic interactions in bacterial communities.

Freilich S, Zarecki R, Eilam O, Segal ES, Henry CS, Kupiec M, Gophna U, Sharan R, Ruppin E.

Nat Commun. 2011 Dec 13;2:589. doi: 10.1038/ncomms1597.

PMID:
22158444
6.

Improving the reporting of adverse drug reactions in the hospital setting.

Pushkin R, Frassetto L, Tsourounis C, Segal ES, Kim S.

Postgrad Med. 2010 Nov;122(6):154-64. doi: 10.3810/pgm.2010.11.2233. Review.

PMID:
21084792
7.

Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: results from the European Postmarketing Surveillance program.

Beghetti M, Hoeper MM, Kiely DG, Carlsen J, Schwierin B, Segal ES, Humbert M.

Pediatr Res. 2008 Aug;64(2):200-4. doi: 10.1203/PDR.0b013e318179954c.

PMID:
18414142
8.

Results of European post-marketing surveillance of bosentan in pulmonary hypertension.

Humbert M, Segal ES, Kiely DG, Carlsen J, Schwierin B, Hoeper MM.

Eur Respir J. 2007 Aug;30(2):338-44. Epub 2007 May 15.

9.

Risk management strategies in the postmarketing period : safety experience with the US and European bosentan surveillance programmes.

Segal ES, Valette C, Oster L, Bouley L, Edfjall C, Herrmann P, Raineri M, Kempff M, Beacham S, van Lierop C.

Drug Saf. 2005;28(11):971-80. Review.

PMID:
16231952
10.
11.

Maintaining communication in a time of uncertainty.

Segal ES.

Arch Fam Med. 1995 Dec;4(12):1066-7.

PMID:
7496556
12.

The determinants of successful self-catheterization programs in children with myelomeningoceles.

Segal ES, Deatrick JA, Hagelgans NA.

J Pediatr Nurs. 1995 Apr;10(2):82-8. Review.

PMID:
7752045

Supplemental Content

Loading ...
Support Center